clinicopathologic study of Ki-67 proliferation index in colorectal carcinoma

To investigate Ki-67 immunoexpressions in colorectal cancer and analyze possible correlations with variable clinicopathological prognostic factors. A cross-sectional study of tissue sections from 50 formalin-fixed and paraffin-embedded tumor specimens were examined at the Histopathology Laboratory of Rezgary Teaching Hospital in Erbil, Iraq between January 2010 and July 2011. Ki-67 labeling index is calculated immunohistochemically using the monoclonal antibody MIB-1, and the standard streptavidin-biotin immunoperoxidase method. The clinicopathologic and prognostic features were statistically analyzed. Over-expression of Ki-67 proliferation protein was found in 31 [62%] cases. Statistical analyses revealed a significant relation between Ki-67 proliferation index and histologic type [p=0.005] and tumor grade [p=0.018]; but no significant relation was calculated with the other clinicopathological parameters such as age, gender, tumor's size, site, depth, stage, nodal status, and vascular invasion [p>0.05]. Ki-67 immune overexpression is a frequent finding in our colorectal cancer cases; but it is not enough to monitor Ki-67 proliferation index alone for prognosis in colorectal cancer

Immunoexpression of p53 and p21 [WAF1/CIP1] proteins in colorectal cancer: correlation with clinicopathological parameters

Both p53 and p21 [WAF1/CIP1] proteins belong to the cell cycle-regulating family of proteins, and the loss of their activity seems to be one of the most important regulatory mechanisms of carcinogenesis in colorectal cancer. The aim of this study was to evaluate the tumor suppressor genes p53 and p21 [WAF1/CIP1] expressions in colorectal cancer and assessment the relationship between p2 [WAF1/CIP1] and p53 immunoreactivity with special emphasis on the prognostic significance of their expression with variable clinicopathologic parameters. Tissue sections from 50 formalin-fixed and paraffin-embedded tumor specimens were examined. The standard streptavidin-biotin immunoperoxidase method was used for immunostaining of p53 protein and p2[WAF1/CIP1] protein.The extent of positive p53 and p21 [WAF1/CIP1] staining was graded semiquantitatively. The clinicopathologic and prognostic features were statistically analyzed. Over-expression of p53 and p2l [WAF1/CIP1] were found in 27 cases [54%] and 22 cases [44%] respectively. Statistical analyses revealed a highly significant correlation between p21 [WAF1/CIP1] and p53 immunopositivity [p=0.003]; but no significant correlation could be calculated between p53 or p21 [WAF1/CIP1] proteins expression with the Clinicopathological parameters such as [age, sex, tumor size, gender, TNM staging, and vascular invasion] except there was significant statistical correlation of p53 expression with tumor type [p<0.05]. Our investigation results suggest that p53 and p2l [WAF1/CIP1] immunoexpression are common findings in colorectal cancer and the induction of p21 [WAF1/CIP1] occur in a p53-dependent or independent pathways

Metabolic syndrome and serum leptin levels in Erbil population

Metabolic syndrome is a potent risk factor for cardiovascular diseases [CVDs], has not been adequately explored in Erbil individuals and its relation to leptin hormone. The present study aim to evaluate such a relationship between serum leptin and metabolic syndrome in Erbil individuals. samples collection were carried out in Razgary Teaching Hospital, 45 cases with metabolic syndrome and 30 healthy control subjects, anthropometric variables measurements [blood pressure, body weight, body height, body mass index] and biochemical tests: fasting, serum glucose, serum triglycerides, high-density lipoprotein cholesterol and serum leptin were obtained from the study samples. Serum leptin levels were significantly higher in females in comparison to the males in metabolic syndromes group [with median 53.6 vs 23.8 ng/dl with p value < 0.05] with also present statistical significant difference in leptin between metabolic syndrome group and control group in both males and females. No important association between serum leptin and each of selected criteria of metabolic syndrome. The observed case-control difference in serum leptin is mainly attributed to gender and body mass index [bmi] differences and not a function of metabolic syndrome itself. Among subjects with metabolic syndrome, only age, gender and body mass index were important in determining the magnitude of serum leptin among cases groups